Food and Drug Administration

Gastrointestinal Drugs Advisory Committee

March 6, 2003


Emend (aprepitant)


The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Prevention of Chemotherapy-Induced Nausea and Vomiting - An Unmet Medical Need, Dr. Dennis Erb, PhD, Merck Research Lab. (HTM) (PPT)

Drug Interactions of Aprepitant, Dr. Venkat Jarugula, PhD, FDA (HTM) (PPT)

Briefing on Aprepitant, Dr. Gary Della'Zanna, DO, MSc, FDA (HTM) (PPT)